Total raised in public, private and other financings of biotech companies, comparing 2019 vs. 2018.

Year-to-date money raised in public, private and other financings of biopharma companies.

Centogene BV filed to sell 4 million common shares on Nasdaq for between $14 and $16 in an IPO expected to raise $60 million at the midpoint.

“We’re in a global market. We need to stop being parochial and work globally from the beginning.”

The FDA’s Janet Woodcock, director of the Center for Drug Evaluation and Research, testified before a House subcommittee on the national security risk raised by U.S. reliance on China exports of active pharmaceutical ingredients (API).

Biotech money raised to-date and by month in 2019, including public, private and other financings.

Follow-ons completed by biopharma companies in October 2019.

Completed and pending initial public offerings by biopharma companies in October 2019.

Private placements and other private financings of public biopharma companies in October 2019.